Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BMY vs CMCSA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BMY Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)

BMY Overall Winner 6-Pillar Tally: BMY 3 – 3 CMCSA Matrix Metrics: BMY 8 – 2 CMCSA

As of Nov 20, 2026, Bristol-Myers Squibb Co. (BMY) is the stronger overall head-to-head candidate over Comcast Corp (CMCSA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BMY carries a Unified Composite Score of 48.9/100 (HOLD) at $58.80 (8.8x Forward P/E, 32.4% operating margin), whereas CMCSA carries 32.8/100 (SELL) at $24.90 (7.1x Forward P/E, 14.7% operating margin).

  • Technical & Structure Timing Caution: BMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.5); meanwhile CMCSA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 59.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMY vs CMCSA
BMY NYSE Head-to-Head Winner
Bristol-Myers Squibb Co.
Pharmaceutical Preparations
$58.80
+0.79% 1D
Market Cap $119.3B
TTM Revenue $50.0B
Forward P/E 8.8x
Beta / 30D Vol 0.16β · 28% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 70.0 Mom 46.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.8%), weak momentum, RSI 39
RSI-14: 39.5 · SMA20: $61.82 · SMA50: $61.45
CMCSA NASDAQ
Comcast Corp
Cable & Other Pay Television Services
$24.90
+0.16% 1D
Market Cap $88.3B
TTM Revenue $123.0B
Forward P/E 7.1x
Beta / 30D Vol -0.01β · 32% Vol
Unified Composite Score
32.8 / 100 SELL
Tech 20.0 Fund 44.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 60
RSI-14: 59.9 · SMA20: $24.14 · SMA50: $22.92

6-Pillar Scorecard Institutional Category Breakdown (BMY 3 – 3 CMCSA)

Columns: Metric · BMY · CMCSA
1. Valuation Multiples CMCSA
Forward P/E 8.8x 7.1x
Trailing P/E 12.9x 7.9x
PEG Ratio 16.33x 1.37x
EV / Revenue 3.1x 1.4x
2. Growth & Scale BMY
Revenue Growth (YoY) +6.9% -6.1%
Earnings Growth (YoY) -2.8% +7.8%
TTM Revenue (USD) $50.0B $123.0B
Market Cap $119.3B $88.3B
3. Profitability & Quality BMY
Gross Margin 70.5% 69.8%
Operating Margin 32.4% 14.7%
Net Profit Margin 18.5% 9.2%
Return on Equity (ROE) 44.0% 11.4%
4. Balance Sheet & Cash Flow BMY
Cash Generation (TTM) $9.29B $17.1B
Cash Flow Margin 18.6% 13.9%
Net Cash / Leverage $35.2B Net Debt (1.91x D/E) $79.8B Net Debt (0.94x D/E)
Dividend Yield 4.23% 5.23%
5. Options & Positioning CMCSA
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 34.5% (24th %ile) 36.3% (30th %ile)
Put/Call OI Skew 1.25x (Put-Skewed) 0.41x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CMCSA
OpEx & R&D Intensity 38.1% of Rev ($19.1B) 55.1% of Rev ($67.8B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Telecom Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMY (8) vs CMCSA (2)
Institutional Metric BMY CMCSA Criterion Row Edge
Market Capitalization
Scale
$119.3B $88.3B Larger Scale BMY
Trailing P/E Ratio
Valuation
12.9x 7.9x Lower Multiple CMCSA
Forward P/E Ratio
Valuation
8.8x 7.1x Lower Multiple CMCSA
Revenue Growth (YoY)
Growth
+6.9% -6.1% Higher Growth BMY
Operating Margin (TTM)
Profitability
32.4% 14.7% Higher Margin BMY
Net Profit Margin
Profitability
18.5% 9.2% Higher Margin BMY
Return on Equity (ROE)
Capital Efficiency
44.0% 11.4% Higher ROE BMY
52-Week Range Position
Momentum
58% ($45–$69) 36% ($20–$33) Stronger Trend BMY
Beta / 30D Volatility
Risk Regime
0.16β · 28% Vol -0.01β · 32% Vol Lower Realized Risk BMY
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 32.8 / 100 (SELL) Higher Composite BMY
Trailing 12M Revenue (USD)
Operating Scale
$50.0B $123.0B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.5% 69.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
16.33x PEG · 3.1x EV/Rev 1.37x PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$9.29B ($35.2B Net Debt (1.91x D/E)) $17.1B ($79.8B Net Debt (0.94x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CMCSA +15.69 pp
BMY: -6.67% · CMCSA: +9.02%
3M Horizon CMCSA +4.75 pp
BMY: -12.6% · CMCSA: -7.85%
6M Horizon BMY +0.1 pp
BMY: -1.11% · CMCSA: -1.21%
1Y Horizon BMY +35.74 pp
BMY: +28.41% · CMCSA: -7.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BMY Revenue CMCSA Revenue BMY Op. Margin CMCSA Op. Margin Margin Leader
FY2018 $22.6B $94.5B 21.8% 20.1% BMY
FY2019 $26.1B $108.9B 13.2% 19.4% CMCSA
FY2020 $42.5B $103.6B -21.2% 16.9% CMCSA
FY2021 $46.4B $116.4B 15.1% 17.9% CMCSA
FY2022 $46.2B $121.4B 13.7% 11.6% BMY
FY2023 $45.0B $121.6B 17.8% 19.2% CMCSA
FY2024 $48.3B $123.7B -18.5% 18.8% CMCSA
FY2025 $48.2B $123.7B 14.6% 16.7% CMCSA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMY CONSOLIDATION
55d in phase · OBV DISTRIBUTION
Current IV 34.5%
IV Percentile 24th %ile
Put/Call OI Skew 1.25x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact BMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CMCSA CONSOLIDATION
61d in phase · OBV NEUTRAL
Current IV 36.3%
IV Percentile 30th %ile
Put/Call OI Skew 0.41x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CMCSA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $62.93 · IV 34.2%

BMY vs. CMCSA: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of BMY ($6,293) vs. CMCSA ($2,560) against risk-defined 5-day vertical and put-wall option structures.

BMY Spot $62.93 · IV 34.2%
BMY Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $62.5 / $67.5 Bull Call Spread

Buy 1x $62.5C · Sell 1x $67.5C · 31d

Net Entry $197 Debit
T+5d @ +5% Move +$100 (+51%)
Max Risk / Buffer $197 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $60 / $57.5 Bull Put Spread

Sell 1x $60P · Buy 1x $57.5P · 31d

Net Entry $61 Credit
Max Credit / Yield +$61 (+32.3% RoM)
Max Risk / Buffer -5.6% Cushion ($189 Mgn)
5d Edge & Liquidity 71% PoP · Liq A
Simulate 5-Day Payoff →
CMCSA Spot $25.60 · IV 34.7%
CMCSA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $25 / $27.5 Bull Call Spread

Buy 1x $25C · Sell 1x $27.5C · 31d

Net Entry $104 Debit
T+5d @ +5% Move +$47 (+46%)
Max Risk / Buffer $104 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $24 / $22.5 Bull Put Spread

Sell 2x $24P · Buy 2x $22.5P · 31d

Net Entry $56 Credit
Max Credit / Yield +$56 (+23.0% RoM)
Max Risk / Buffer -7.3% Cushion ($244 Mgn)
5d Edge & Liquidity 75% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMY Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $119.3B market capitalization and 32.4% operating margin.
OpEx & R&D Reinvestment 38.1% of Rev ($19.1B)
90D Engineering Disclosures 0 Published
CMCSA Moat Profile Cyclical / Execution-Driven Positioning
Telecom Services Operator
Competes within the Telecom Services value chain with $88.3B market capitalization and 14.7% operating margin.
OpEx & R&D Reinvestment 55.1% of Rev ($67.8B)
90D Engineering Disclosures 0 Published

Investor FAQ BMY vs CMCSA Key Questions & Quantitative Answers

As of Nov 20, 2026, Bristol-Myers Squibb Co. (BMY) is the stronger overall head-to-head candidate over Comcast Corp (CMCSA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BMY carries a Unified Composite Score of 48.9/100 (HOLD) at $58.80 (8.8x Forward P/E, 32.4% operating margin), whereas CMCSA carries 32.8/100 (SELL) at $24.90 (7.1x Forward P/E, 14.7% operating margin). Technical & Structure Timing Caution: BMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.5); meanwhile CMCSA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 59.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BMY leads the Growth & Scale pillar: BMY posts +6.9% YoY revenue growth and -2.8% YoY earnings growth on $50.0B TTM revenue (70.5% gross margin, 32.4% operating margin), compared with CMCSA at -6.1% YoY revenue growth and +7.8% YoY earnings growth on $123.0B TTM revenue (69.8% gross margin, 14.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BMY cumulative revenue shifted +113.6% while CMCSA shifted +30.9%. In operating R&D and SG&A reinvestment, BMY deploys 38.1% of Rev ($19.1B) (0 90-day corporate R&D disclosures) versus 55.1% of Rev ($67.8B) (0 disclosures) for CMCSA.

CMCSA screens cheaper on headline valuation multiples. BMY trades at 8.8x Forward P/E, 12.9x Trailing P/E, 16.33x PEG, and 3.1x EV/Revenue (18.6% FCF margin), whereas CMCSA trades at 7.1x Forward P/E, 7.9x Trailing P/E, 1.37x PEG, and 1.4x EV/Revenue (13.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMY (44.0% ROE) versus CMCSA (11.4% ROE) capital efficiency.

In options market volatility and institutional positioning, BMY carries 34.5% implied volatility (24th %ile, Compressed (<25th %ile)), a 1.25x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.16β · 28% Vol realized risk). By comparison, CMCSA carries 36.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.01β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.